Relmada Therapeutics Inc (RLMD) - Total Liabilities
Based on the latest financial reports, Relmada Therapeutics Inc (RLMD) has total liabilities worth $16.63 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore RLMD long-term investments to assets to see how much of total assets are deployed in long-term investments.
Relmada Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Relmada Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see RLMD total asset value.
Relmada Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Relmada Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Poly Union Chemical Holding Group Co Ltd
SHE:002037
|
China | CN¥13.04 Billion |
|
DOUBLED.INTERAC.SP.ADS/20
F:DDI
|
Germany | €90.16 Million |
|
Global Dominion Access S.A
MC:DOM
|
Spain | €1.36 Billion |
|
Chengdu KSW Technologies Co. Ltd. A
SHG:688283
|
China | CN¥167.47 Million |
|
Natural Gas Services Group Inc
NYSE:NGS
|
USA | $308.38 Million |
|
Zhejiang Jiaxin Silk Corp Ltd
SHE:002404
|
China | CN¥1.47 Billion |
|
Beijing Hanyi Innovation Technology Co. Ltd. A
SHE:301270
|
China | CN¥191.34 Million |
|
Citizens & Northern Corp
NASDAQ:CZNC
|
USA | $2.81 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Relmada Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Relmada Therapeutics Inc (RLMD) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Relmada Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Relmada Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Relmada Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.49 Million | -27.24% |
| 2024-12-31 | $10.30 Million | -15.57% |
| 2023-12-31 | $12.19 Million | -2.20% |
| 2022-12-31 | $12.47 Million | -17.21% |
| 2021-12-31 | $15.06 Million | +19.50% |
| 2020-12-31 | $12.60 Million | +764.53% |
| 2019-12-31 | $1.46 Million | -82.97% |
| 2018-12-31 | $8.56 Million | +521.89% |
| 2017-12-31 | $1.38 Million | -57.00% |
| 2016-12-31 | $3.20 Million | -79.45% |
| 2015-12-31 | $15.58 Million | 0.00% |
| 2014-12-31 | $15.58 Million | -42.01% |
| 2014-06-30 | $26.87 Million | 0.00% |
| 2013-12-31 | $26.87 Million | +384025.37% |
| 2012-12-31 | $7.00K | -- |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more